Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive PH+ Acute Leukemia - A Multi-Center Trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ciclosporin; Dasatinib; Fludarabine; Imatinib; Mycophenolate mofetil; Nilotinib
- Indications Chronic myeloid leukaemia; Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 29 Jan 2020 Biomarkers information updated
- 30 Oct 2013 Planned end date changed from 1 Jul 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 08 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.